Search
forLearn
5 / 801 resultslearn TeraCeutic™
learn enoxolone
learn PENTAVITIN®
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ results
research Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
Blocking EGFR in skin cells doesn't majorly increase inflammation markers.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Tebentafusp-tebn (Kimmtra®)
Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
research Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
Community Join
5 / 1000+ resultscommunity RU/Pyrilutamide access and purchase
The conversation is about accessing and purchasing RU58841 or Pyrilutamide for hair loss treatment, with mentions of alternatives like Breezula. Users discuss price differences in various countries and suggest websites like rudirect.com for purchasing.
community Pyrilutamide / KX-826 | Discussion EU
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
community When will Breezula be released and how does it compare to KX-826?
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Pyrludimide (KX-826) or Breezula (clascoterone)
The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.